Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Core Insights - Serina Therapeutics is advancing SER-270, a novel once-weekly injectable VMAT2 inhibitor aimed at treating tardive dyskinesia (TD), addressing significant adherence and access challenges for patients [1][2][3] Group 1: Product Development - SER-270 utilizes Serina's proprietary POZ polymer technology for long-acting, subcutaneous administration, providing a transformative alternative to existing oral VMAT2 inhibitors [2] - The product is designed specifically for underserved TD patients who struggle with daily medication adherence, including those on long-acting injectable antipsychotics [2][7] Group 2: Market Opportunity - TD is a disabling movement disorder primarily affecting patients with chronic psychiatric conditions, with less than 30% of U.S. TD patients diagnosed and fewer than half receiving treatment [3] - The U.S. TD market exceeded $3.7 billion in sales in 2024 and is projected to grow to $5.4 billion by 2030, highlighting the demand for therapies that improve adherence and access [3] Group 3: Expansion Plans - Serina plans to explore the development of POZ-VMAT2i for chorea associated with Huntington's disease, which may offer significant advantages over current oral therapies for affected patients and caregivers [5][6] Group 4: Patient-Centric Approach - The once-weekly injectable format is critical for non-compliant patients, including those in institutional settings and those with dysphagia, thereby improving access to treatment [7]